

deferasirox, oral (JADENU SPRINKLE)
JADENU SPRINKLE (deferasirox, oral)

Diagnosis Considered for Coverage:

- Chronic iron toxicity secondary to transfusional iron overload (transfusional hemosiderosis)

Coverage Criteria:

For deferasirox sprinkle and diagnosis listed above:

- Intolerance or contraindication to deferasirox suspension tablet (Exjade) not expected with Jadenu Sprinkle, **and**
- Dose does not exceed 28 mg/kg per day.

For brand-name Jadenu Sprinkle:

- Meets above coverage criteria for generic, and
- Allergic or intolerable side effect to the generic formulation.

Coverage Duration: Length of benefit

Effective: 9/01/2020